Any current/future new fundraising through debt or equity?

There is no specific mention of any current or future fundraising through debt or equity in the provided transcript. The company has been focusing on capex projects funded internally, with an annual capex range of INR 80 to 100 crores. The management discussed ongoing capex for pharma intermediates (INR 60 crores) and OAP (INR 15 crores) but did not indicate raising funds through equity or debt. They mentioned managing working capital and improving cash flows post-Sarigam incident, with some reduction in short-term borrowing. No explicit plans for raising debt or equity were stated during the

Any current/future capex/capital investment/strategic investment?

Ongoing capex includes INR 15 crores for OAP (Ortho Anisic Phenol) and INR 60 crores for pharma intermediates, totaling around INR 75 crores. Pharma intermediates capex is completed with trial runs done and awaiting government approvals (expected by end Q3 FY '23). OAP capex is still ongoing with trial runs and some additional capex expected. After commissioning these projects, further capex plans are unclear; typically, the company does INR 80-100 crores of annual capex. The company is also analyzing new product opportunities, potentially involving a modest capex of around INR 40-45 crores if

Future growth expectations in sales/revenue/volumes?

The company expects revenue growth of 5% to 10% for the current financial year (FY23), targeting INR 1,000 to 1,100 crores on a standalone basis. For FY24 and beyond, a growth of around 30% is anticipated with full ramp-up of PAP (para Aminophenol), OAP (other agrochemicals project), and pharma intermediates. Pharma intermediates plant expected to reach around 45-50% utilization in initial quarters of FY24 and full utilization by end of FY24, targeting about INR 50 crores revenue at full capacity. Continuous process for PAP expected to increase production capacity from 500 to 1,000 metri

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a turnover of around INR 60 crores from the pharma intermediates product, with an asset turnover of approximately 1x, potentially a little more. Margins for pharma intermediates are expected to be aligned with company-level margins; specific product margins are not disclosed. Revenues were impacted by the Sarigam incident, causing a top-line loss of around 15-20% quarterly; full production recovery is expected by March, with growth of 5-10% by year-end on a standalone basis. For FY '23, an average EBITDA margin of around 17% is anticipated, improving from earlier quarters d

Current/ Expected Orderbook/ Pending Orders?

The Sarigam plant had an incident impacting production and order fulfillment, causing a phased restart and lag in order execution. The management mentioned a lag in fulfilling certain orders due to the Sarigam plant being non-operational and phased ramp-up post-incident. Global demand issues, especially in Europe due to geopolitical and energy crisis, have also affected export order volumes. The company expects a recovery in production and order execution once the Sarigam plant stabilizes and global demand improves. New product development and capex for pharma intermediates and OAP are underwa

Valiant Organics LtdQ2 FY23Chemicals & Petrochemicals

Valiant Organics Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹477P/E: 22.8Market Cap: ₹1.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The company expects revenue growth of 5% to 10% for the current financial year (FY23), targeting INR 1,000 to 1,100 crores on a standalone basis.
For FY24 and beyond, a growth of around 30% is anticipated with full ramp-up of PAP (para Aminophenol), OAP (other agrochemicals project), and pharma intermediates.
Pharma intermediates plant expected to reach around 45-50% utilization in initial quarters of FY24 and full utilization by end of FY24, targeting about INR 50 crores revenue at full capacity.
Continuous process for PAP expected to increase production capacity from 500 to 1,000 metric tons per month once technical challenges are resolved, likely in upcoming financial years.
Volume recovery at Sarigam plant to full original levels (~4,000-4,500 tons per quarter) by Q4 FY23.
Overall growth driven by stabilizing raw material prices, operational improvements, and new product launches.

Margin guidance

Category 3

The company expects a turnover of around INR 60 crores from the pharma intermediates product, with an asset turnover of approximately 1x, potentially a little more.
Margins for pharma intermediates are expected to be aligned with company-level margins; specific product margins are not disclosed.
Revenues were impacted by the Sarigam incident, causing a top-line loss of around 15-20% quarterly; full production recovery is expected by March, with growth of 5-10% by year-end on a standalone basis.
For FY '23, an average EBITDA margin of around 17% is anticipated, improving from earlier quarters due to stabilized raw material costs; margins of 17-18% projected full-year.
Post stabilization, the company targets 30% growth in the following year, driven by full utilization of PAP, along with OAP and pharma intermediates ramp-up.
Annual capex is targeted around INR 80-100 crores to support growth.
Long-term ROC improvements are expected but uncertain if pre-challenge historic levels (40%-60%) will be reached soon.

See what Valiant Organics Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any current or future fundraising through debt or equity in the provided transcript.
The company has been focusing on capex projects funded internally, with an annual capex range of INR 80 to 100 crores.
The management discussed ongoing capex for pharma intermediates (INR 60 crores) and OAP (INR 15 crores) but did not indicate raising funds through equity or debt.
They mentioned managing working capital and improving cash flows post-Sarigam incident, with some reduction in short-term borrowing.
No explicit plans for raising debt or equity were stated during the Q&A or management comments.

Order book

The Sarigam plant had an incident impacting production and order fulfillment, causing a phased restart and lag in order execution.
The management mentioned a lag in fulfilling certain orders due to the Sarigam plant being non-operational and phased ramp-up post-incident.
Global demand issues, especially in Europe due to geopolitical and energy crisis, have also affected export order volumes.
The company expects a recovery in production and order execution once the Sarigam plant stabilizes and global demand improves.
New product development and capex for pharma intermediates and OAP are underway, with expectations to increase revenues and order inflow upon commissioning.
No specific quantitative orderbook or pending order values were disclosed in the transcript.

See what Valiant Organics Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Ongoing capex includes INR 15 crores for OAP (Ortho Anisic Phenol) and INR 60 crores for pharma intermediates, totaling around INR 75 crores.
Pharma intermediates capex is completed with trial runs done and awaiting government approvals (expected by end Q3 FY '23).
OAP capex is still ongoing with trial runs and some additional capex expected.
After commissioning these projects, further capex plans are unclear; typically, the company does INR 80-100 crores of annual capex.
The company is also analyzing new product opportunities, potentially involving a modest capex of around INR 40-45 crores if successful.
Focus remains on stabilizing current projects before launching new large investments.
The pharma intermediates plant will be captive to Aarti Pharmalabs.
Continuous development and trials ongoing to shift PAP production from batch to continuous process for efficiency gains.

Track Valiant Organics Ltd — get its next earnings analysis in your feed

How does Valiant Organics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisValiant Organics Ltd

Rev 3Mar 3

See where Valiant Organics Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Valiant Organics Ltd rank in Chemicals & Petrochemicals?

Compare Valiant Organics Ltd against every Chemicals & Petrochemicals company (Q2 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Valiant Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Valiant Organics Ltd Q2 FY23 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Valiant Organics Ltd rank in Chemicals & Petrochemicals?

Continue your research

What Valiant Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season